目的 探讨乐脉颗粒联合鼠神经生长因子治疗脑梗死的临床疗效。方法 选取2015年10月-2016年10月在成都市天府新区人民医院进行治疗的脑梗死患者96例，随机分为对照组（48例）和治疗组（48例）。对照组肌肉注射注射用鼠神经生长因子，30 μg溶于注射用水2 mL，1次/d。治疗组在对照组的基础上口服乐脉颗粒，2袋/次，3次/d。两组患者均连续治疗4周。评价两组患者临床疗效，同时比较治疗前后两组患者血清学指标和神经功能缺损评分变化。结果 治疗后，对照组临床总有效率为81.25%，显著低于治疗组的97.92%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清单核细胞趋化蛋白-1（MCP-1）、神经元特异性烯醇化酶（NSE）、S100β和可溶性细胞间黏附分子-1（sICAM-1）水平明显降低，同组比较差异具有统计学意义（P<0.05）；且治疗后治疗组上述血清学指标水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组神经功能缺损评分均明显下降，同组比较差异具有统计学意义（P<0.05）；且治疗后治疗组患者神经功能缺损评分低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 乐脉颗粒联合鼠神经生长因子治疗脑梗死的效果显著，可明显改善患者神经功能，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Lemai Granules combined with mouse nerve growth factor in treatment of cerebral infarction. Methods Patients (96 cases) with cerebral infarction in Chengdu Tianfu New District People's Hospital from October 2015 to October 2016 were randomly divided into control (48 cases) and treatment (48 cases) groups. Patients in the control group were intramuscular injection administered with Mouse Nerve Growth Factor for injection, 30 μg dissolved into water for injection 2 mL, once daily. Patients in the treatment group were po administered with Lemai Granules on the basis of the control group, 2 bags/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, clinical efficacy was evaluated, and the change of the serological indexes, and neurological function defect scale in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the MCP-1, NSE, S100β, and sICAM-1 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the neurological function defect scale in two groups was significantly decreased, and there were differences in the same group (P<0.05). And the neurological function defect scale in the treatment group was obviously lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Lemai Granules combined with mouse nerve growth factor has significant effect in treatment of cerebral infarction, can significantly improve the neurological function, which has a certain clinical application value.